Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
- UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001 October 23, 2026
Soon to Be Phase 1: ADI‑212 Off The Shelf CAR T Therapy for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxFDA has cleared the way for an early clinical trial of a new, off‑the‑shelf cell therapy designed to tackle metastatic castration‑resistant prostate cancer, a late and difficult stage of the disease. The investigational product, referred to in regulatory filings as ADI‑212, is a gene‑edited, “armored” gamma delta CAR T cell therapy that targets prostate‑specific membrane […]
Daily Adaptive Radiotherapy After Prostate Surgery: Early Results from the DART-PHASER Study
/in Observational/by MaxA new clinical study is testing a smarter way to give radiation after prostate surgery. The approach, called daily adaptive radiotherapy, uses artificial intelligence to adjust the treatment plan every day based on how the patient’s anatomy looks at that moment. Early results from the first 42 patients in the DART-PHASER trial suggest the method […]
Forcing Resistant Prostate Cancer Back into Treatment Range: eIF4E Could Help
/in Preclinical Research/by MaxProstate cancer often becomes dangerous because the tumor cells can change their identity to escape treatment. At first, most prostate cancers are “luminal”: they depend on the androgen receptor (AR), a protein that acts like a growth switch turned on by male hormones. Drugs that block this receptor, such as enzalutamide, usually work well at […]
UPDATE: MRT-2359 Plus Apalutamide Combination Enters Phase 2 Trial for AR-Mutated Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxA new phase 2 trial is evaluating MRT-2359 in combination with apalutamide for patients with androgen receptor (AR) mutation-positive metastatic castration-resistant prostate cancer, an advanced disease that may become resistant to standard hormone-directed treatments. The first patient has been dosed in the MODeFIRe-1 study, which plans to enroll up to 25 patients. Participants must have […]
Soon to be Phase 1 Trial: AK157D1 a New B7‑H3–Targeted ADC in Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxThe investigational B7‑H3–targeting antibody–drug conjugate AK157D1, recently cleared for a Phase I trial in advanced solid tumors, is especially compelling from a prostate cancer perspective because B7‑H3 (CD276) is one of the most uniformly expressed and biologically aggressive surface targets across the full disease continuum, from hormone‑sensitive to castration‑resistant and neuroendocrine phenotypes. Unlike PSMA, which […]
Drug Combination Shows Promise Against Treatment-Resistant Prostate Cancer
/in Drug repurposing, Preclinical Research/by MaxA University of Michigan study suggests that combining two types of drugs could offer a new approach to treating advanced, treatment-resistant prostate cancer. The research focused on tumors that have changed their identity through a process called transdifferentiation. These tumors can become more aggressive and may no longer respond well to standard treatments that target […]
How Prostate Cancer Hijacks Amino Acids to Beat Hormone Therapy
/in Preclinical Research/by MaxProstate cancer cells can outsmart hormone therapy by rewiring how they use nutrients, and a new preclinical study from Weill Cornell Medicine shows exactly how. Published in Nature Metabolism, the work reveals that tumors hijack the metabolism of two common amino acids, isoleucine and valine, to boost cholesterol production inside the tumor. That extra cholesterol […]
pTVG-HP DNA Vaccine Shows Long-Term Survival Benefit in Recurrent Prostate Cancer
/in Clinical Trial, Non-Metastatic, Phase 2/by MaxLong-term follow-up from a randomized phase 2 trial suggests that the DNA vaccine pTVG-HP (MVI-816) may significantly extend overall survival in men with PSA-recurrent, non-metastatic, castration-sensitive prostate cancer. The findings are particularly notable because the vaccine did not improve the study’s original primary endpoint of 2-year metastasis-free survival. The trial enrolled 99 men whose prostate […]